Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.

ABSTRACT: Current hormonal therapies for prostate cancer are effective initially, but inevitably tumours progress to an advanced, metastatic stage, often referred to as 'androgen independent'. However, the androgen receptor (AR) signalling pathway is still key for their growth. It is speculated that tumours escape hormonal control via reduction in corepressor proteins. Manipulating such proteins is thus a potential therapeutic strategy to halt or even reverse tumour progression. We aimed to elucidate the effects of altering levels of the AR corepressor and androgen-target protein prohibitin (PHB) on prostate tumour growth. Prostate cancer cells incorporating an integrated androgen-responsive reporter gene and stably expressing vectors to inducibly overexpress or knockdown PHB were generated and used

SUBMITTER: Dart DA 

PROVIDER: S-EPMC2782800 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature